BSX
Mark your calendar
Boston Scientific is headed for the earnings confessional on Wednesday, April 22, before the market opens. Analysts are looking for Q1 2026 EPS of $0.793 on revenue of $5.186 billion, while the company itself has already put some numbers on the board with guidance of $0.780 to $0.800 in EPS for the quarter.
Why investors are paying attention
This is one of those calls where the headline number matters, sure — but the real drama is in the fine print. Boston Scientific is also dealing with a fresh batch of securities-class-action chatter, with firms alleging it may have hidden weakness in electrophysiology demand. Translation: even a decent earnings print could come with some legal static in the background.
The other stuff hanging over the call
There’s a bit of a soap opera around the stock right now:
- CEO Michael Mahoney sold 160,901 shares back in February
- Analysts still sound mostly upbeat, with a consensus “Moderate Buy” and an average target around $102.91
- Institutional ownership is heavy, so big funds are very much along for the ride
Big picture
If Boston Scientific comes in close to expectations and keeps its full-year EPS guide of $3.430 to $3.490 intact, the market may treat this like a standard quarterly checkup. But if guidance gets wobbly or the legal overhang starts to feel more expensive than annoying, you could see the stock do the earnings-call equivalent of tripping over its own shoelaces.